摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4-环氧四氢呋喃 | 285-69-8

中文名称
3,4-环氧四氢呋喃
中文别名
3,6-二氧杂双环[3.1.0]己烷
英文名称
3,4-epoxytetrahydrofuran
英文别名
3,6-dioxa-bicyclo[3.1.0]hexane;2,5-dihydrofuran epoxide;3,6-Dioxabicyclo[3.1.0]hexane
3,4-环氧四氢呋喃化学式
CAS
285-69-8
化学式
C4H6O2
mdl
MFCD00800639
分子量
86.0904
InChiKey
AIUTZIYTEUMXGG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    44°C 10mm
  • 密度:
    1.237
  • 闪点:
    >38℃
  • 稳定性/保质期:
    在常温常压下保持稳定,应避免与不相容的材料、火源及热源接触。它会与强氧化剂、强酸和强碱发生反应。

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    6
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    21.8
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险等级:
    3
  • 危险品标志:
    Xi
  • 安全说明:
    S16,S23,S26,S36/37/39
  • 危险类别码:
    R10,R36/37/38
  • 海关编码:
    2932999099
  • 包装等级:
    I; II; III
  • 危险品运输编号:
    UN 1993
  • 危险类别:
    3
  • 危险性防范说明:
    P501,P240,P210,P233,P243,P241,P242,P280,P370+P378,P303+P361+P353,P403+P235
  • 危险性描述:
    H225
  • 储存条件:
    密封储存,冷藏于阴凉、干燥的库房,并远离火源和易燃易爆区域。

SDS

SDS:5ea7b8ad7c2fa5e8ef902fbe49f37de4
查看
Name: 3 4-Epoxytetrahydrofuran Material Safety Data Sheet
Synonym: None
CAS: 285-69-8
Section 1 - Chemical Product MSDS Name:3 4-Epoxytetrahydrofuran Material Safety Data Sheet
Synonym:None

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
285-69-8 3,4-Epoxytetrahydrofuran ca 100 206-006-1
Hazard Symbols: None Listed.
Risk Phrases: 10

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Flammable.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Vapors may cause dizziness or suffocation.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Vapors may form an explosive mixture with air.
Vapors can travel to a source of ignition and flash back. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Will burn if involved in a fire. Use water spray to keep fire-exposed containers cool. Containers may explode in the heat of a fire. Flammable liquid and vapor. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
For small fires, use dry chemical, carbon dioxide, water spray or alcohol-resistant foam. For large fires, use water spray, fog, or alcohol-resistant foam. Use water spray to cool fire-exposed containers. Water may be ineffective. Do NOT use straight streams of water.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Remove all sources of ignition. Use a spark-proof tool. Provide ventilation. A vapor suppressing foam may be used to reduce vapors.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Ground and bond containers when transferring material. Use spark-proof tools and explosion proof equipment. Avoid contact with eyes, skin, and clothing. Empty containers retain product residue, (liquid and/or vapor), and can be dangerous. Keep container tightly closed. Keep away from heat, sparks and flame. Avoid ingestion and inhalation. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose empty containers to heat, sparks or open flames.
Storage:
Keep away from heat, sparks, and flame. Keep away from sources of ignition. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Flammables-area. Keep refrigerated. (Store below 4C/39F.)

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 285-69-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear colorless to almost colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 44 deg C @ 10.00mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 38 deg C (> 100.40 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: moderately soluble in water
Specific Gravity/Density:
Molecular Formula: C4H6O2
Molecular Weight: 86.09

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, ignition sources, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 285-69-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3,4-Epoxytetrahydrofuran - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: FLAMMABLE LIQUID, N.O.S.*
Hazard Class: 3
UN Number: 1993
Packing Group: III
IMO
Shipping Name: FLAMMABLE LIQUID, N.O.S.
Hazard Class: 3.3
UN Number: 1993
Packing Group: III
RID/ADR
Shipping Name: FLAMMABLE LIQUID, N.O.S.
Hazard Class: 3
UN Number: 1993
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
R 10 Flammable.
Safety Phrases:
S 9 Keep container in a well-ventilated place.
S 16 Keep away from sources of ignition - No
smoking.
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 33 Take precautionary measures against static
discharges.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 285-69-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 285-69-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 285-69-8 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A



制备方法与用途

用途

3,4-环氧四氢呋喃可通过使用多用途双核铬催化剂,从环氧化物中制备各种可降解的聚合物。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3,4-环氧四氢呋喃硫酸 为溶剂, 反应 24.0h, 以72%的产率得到anhydroerythritol
    参考文献:
    名称:
    Silicate Complexes of Sugars in Aqueous Solution
    摘要:
    Certain sugars react readily with basic silicic acid to form soluble 2/1 (sugar/silicic acid) silicate complexes. Failure of monohydroxy compounds to give soluble products under these conditions indicates that the sugar silicates are chelates: five-membered diolato rings. Only furanose forms react. Pyranose sugars are stable under these conditions. Because all glycosides fail to react with silicic acid under these conditions, reaction appears to involve the anomeric position (Cl in aldoses, C2 in ketoses), which has a more acidic hydroxy group. Reaction is completed only when the anomeric hydroxy group is cis to an adjacent hydroxy group. The appropriate furanose form must have sufficient natural abundance and solubility to provide an observable product, as measured by Si-29 and C-13 NMR spectroscopy. These structural and practical constraints rationalize the successful reaction of the monosaccharides ribose, xylose, lyxose, talose, psicose, fructose, sorbose, and tagatose and the disaccharides lactulose, maltulose, and palatinose. Glucose, mannose, galactose, and sucrose, among others, failed to form complexes. This high selectivity for formation of sugar silicates may have ramifications in prebiotic chemistry.
    DOI:
    10.1021/ja031748v
  • 作为产物:
    描述:
    2,5-二氢呋喃间氯过氧苯甲酸 作用下, 以 二氯甲烷 为溶剂, 反应 24.0h, 以58%的产率得到3,4-环氧四氢呋喃
    参考文献:
    名称:
    环氧的有机催化不对称水解
    摘要:
    环氧化合物的水解开环是重要的生物合成转化,也已在工业上应用。我们报道了该反应的第一个有机催化变体,它利用了我们最近发现的通过异二聚作用与手性磷酸对羧酸的活化作用。该方法学模拟了酶促机制,其中涉及酶结合的羧酸盐亲核试剂。新设计的磷酸催化剂显示高立体控制中的desymmetrization内消旋环氧化物。该方法在环状,酰基,芳族和脂族底物上显示出广泛的通用性。我们还将我们的方法应用于简单烯烃的第一个高度对映选择性的抗二羟基化反应中。
    DOI:
    10.1002/anie.201400170
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION<br/>[FR] COMPOSÉS DE BENZYLAMINE SUBSTITUÉS, LEUR UTILISATION EN MÉDECINE, EN PARTICULIER DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE C (VHC)
    申请人:ASTEX THERAPEUTICS LTD
    公开号:WO2013064538A1
    公开(公告)日:2013-05-10
    The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally substituted acyclic C1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is selected from hydrogen and a group R2a; R2a is selected from an optionally substituted acyclic d-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R1 and R2 is other than hydrogen; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 heteroatom ring members selected from N, O and S; R4a is selected from halogen; cyano; C1-4 alkyl optionally substituted with one or more fluorine atoms; C1-4 alkoxy optionally substituted with one or more fluorine atoms; hydroxy-C1-4 alkyl; and C1-2 alkoxy-C1-4 alkyl; R5 is selected from hydrogen and a substituent R5a; and R5a is selected from C1-2 alkyl optionally substituted with one or more fluorine atoms; C1-3 alkoxy optionally substituted with one or more fluorine atoms; halogen; cyclopropyl; cyano; and amino, The compounds have activity against hepatitis C virus and can be used in the prevention or treatment of hepatitis C viral infections.
    该发明提供了以下式(I)的化合物,或其盐、N-氧化物或互变异构体,其中A为CH、CF或氮;E为CH、CF或氮;R0为氢或C1-2烷基;R1a选自CONH2;CO2H;一个可选择取代的非环状C1-8碳氢化合物基团;以及一个可选择取代的含有3至7个环成员的单环碳环或杂环基团,其中0、1、2、3或4个是从O、N和S中选择的杂原子环成员;R2选自氢和一个基团R2a;R2a选自一个可选择取代的非环状d-8碳氢化合物基团;一个可选择取代的含有3至7个环成员的单环碳环或杂环基团,其中0、1或2个环成员是从O、N和S中选择的杂原子环成员;以及一个可选择取代的含有9或10个环成员的双环杂环基团,其中1或2个环成员是氮原子;其中R1和R2中至少一个不是氢;R3选自一个可选择取代的含有0、1、2或3个从N、O和S中选择的杂原子环成员的3至10个成员的单环或双环碳环或杂环环;R4a选自卤素;氰基;C1-4烷基,可选择取代一个或多个氟原子;C1-4烷氧基,可选择取代一个或多个氟原子;羟基-C1-4烷基;和C1-2烷氧基-C1-4烷基;R5选自氢和一个取代基R5a;R5a选自C1-2烷基,可选择取代一个或多个氟原子;C1-3烷氧基,可选择取代一个或多个氟原子;卤素;环丙基;氰基;和氨基。这些化合物对丙型肝炎病毒具有活性,并可用于预防或治疗丙型肝炎病毒感染。
  • [EN] MACROCYCLIC FACTOR VIIA INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES DU FACTEUR VIIA
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013184734A1
    公开(公告)日:2013-12-12
    The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.
    本发明提供了如规范中定义的Formula (I)的化合物,以及包含任何此类新化合物的组合物。这些化合物是Factor VIIa抑制剂,可用作药物。
  • [EN] COMPOUNDS<br/>[FR] COMPOSÉS
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2018137593A1
    公开(公告)日:2018-08-02
    Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    提供了抑制LRRK2激酶活性的新化合物,以及它们的制备方法、含有它们的组合物以及它们在治疗或预防与LRRK2激酶活性相关或以其为特征的疾病中的用途,例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症(ALS)。
  • Enantioselective Cross-Coupling of <i>meso</i>-Epoxides with Aryl Halides
    作者:Yang Zhao、Daniel J. Weix
    DOI:10.1021/jacs.5b01909
    日期:2015.3.11
    The first enantioselective cross-electrophile coupling of aryl bromides with meso-epoxides to form trans-β-arylcycloalkanols is presented. The reaction is catalyzed by a combination of (bpy)NiCl2 and a chiral titanocene under reducing conditions. Yields range from 57 to 99% with 78–95% enantiomeric excess. The 30 examples include a variety of functional groups (ether, ester, ketone, nitrile, ketal
    首次提出了芳基溴化物与内消旋环氧化物形成反式-β-芳基环烷醇的对映选择性交叉亲电偶联。该反应由(bpy)NiCl 2 和手性二茂钛在还原条件下的组合催化。产率范围为 57% 至 99%,对映体过量为 78-95%。这 30 个例子包括各种官能团(醚、酯、酮、腈、缩酮、三氟甲基、磺酰胺、磺酸酯)、芳基和乙烯基卤化物以及五至七元环。一氧化环辛烯向芳基[3.3.0]双环辛醇的转化强烈暗示了碳自由基的中介作用。
  • [EN] 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS<br/>[FR] DÉRIVÉS DE 2-OXO-THIAZOLE EN TANT QU'INHIBITEURS DE A2A ET COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS
    申请人:ITEOS THERAPEUTICS
    公开号:WO2018178338A1
    公开(公告)日:2018-10-04
    The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of Formula (I) for the treatment and/or prevention of cancer. The invention also relates to a process for manufacturing compounds of Formula (I).
    本发明涉及式(I)的化合物或其药用可接受的盐或溶剂化合物。该发明进一步涉及将式(I)的化合物用作A2A抑制剂。该发明还涉及将式(I)的化合物用于治疗和/或预防癌症。该发明还涉及一种制造式(I)化合物的方法。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(2S,4aR,5S,8R,8aR)-8-乙基-4a,5-二羟基-六氢-2H-2,5-环氧色素-4(3H)-酮 阿斯利多 锗(II)氯化二噁烷络合物 试剂5-Methyl-5-propargyloxycarbonyl-1,3-dioxane-2-one 螺二醇 螺[环丙烷-1,7'-[2,3]二氧杂双环[2.2.1]庚烷] 螺[3,6-二氧杂双环[3.1.0]己烷-2,4'-咪唑烷] 薰衣草恶烷 苯乙醛 1,3-丙烷二基缩醛 脱水莫诺苷元 硫脲与2,4,8,10-四氧杂螺[5.5]十一烷-3,9-丙二胺和缩水甘油丁醚的反应产物 硝溴生 盐酸大观霉素 盐酸1,4-二恶烷 甲基 2,3-脱水-beta-D-呋喃核糖苷 甘油缩甲醛 溴化[5-(羟甲基)-2-苯基-1,3-二噁烷-5-基]-N,N,N-三甲基甲铵 溴[4-(1,3-二恶烷-2-基)苯基]镁 溴[3-(1,3-二恶烷-2-基)苯基]镁 溴[2-(1,3-二恶烷-2-基)苯基]镁 溴-1,4-二氧六环复合物 氯甲基聚苯乙烯 敌噁磷 戊氧氯醛 对二恶烷-2,6-二甲醇 奇烯醇霉素 大观霉素 埃玛菌素 吡啶,2-(1,3-二噁烷-2-基)- 反式-5-溴-4-苯基-[1,3]二恶烷 反式-2,5-双-(羟甲基)-1,4-二恶烷 双(4-乙基亚苯基)山梨醇 六氢[1,4]二恶英并[2,3-b]-1,4-二恶英 六氢-2,4,4,7-四甲基-4H-1,3-苯并二氧杂环己 全氟(2-氧代-3,6-二甲基-1,4-二恶烷) 亚苄基-2,2-双(氧基甲基)丙酸 二苯并[b,e][1,4]二噁英,4a,5a,9a,10a-四氢-,溴化氯化(1:2:6) 二苯并[b,e][1,4]二噁英,4a,5a,9a,10a-四氢-,溴化氯化(1:2:5) 二聚丁醇醛 二甲基二恶烷 二甲基2,4:3,5-二-O-亚甲基-D-葡萄糖二酸 二甲基2,4,8,10-四氧杂螺[5.5]十一烷-3,9-二羧酸酯 二甲基-1,4-二恶烷 二甘醇酐 二环[3.1.0]己烷-3-酮,4-亚甲基-1-(1-甲基乙基)-,肟 二氯硼烷二氧六环 二氧六环-d8 二氢壮观霉素 二恶烷 二噁烷甘醇